Form SC 13D/A - General Statement of Acquisition of Beneficial Ownership: [Amend]
SEC Accession No. 0000905718-17-000786
Filing Date
2017-08-14
Accepted
2017-08-14 17:23:24
Documents
1
Group Members
ABINGWORTH BIOVENTURES VI, LP

Document Format Files

Seq Description Document Type Size
1 SC 13D AMENDMENT NO. 1 crispr13dam1aug32017.htm SC 13D/A 148381
  Complete submission text file 0000905718-17-000786.txt   149851
Mailing Address 38 JERMYN STREET LONDON X0 SW1Y 6DN
Business Address 38 JERMYN STREET LONDON X0 SW1Y 6DN 44 (0)20 7534 1500
Abingworth LLP (Filed by) CIK: 0001397144 (see all company filings)

EIN.: 980518585 | State of Incorp.: X0 | Fiscal Year End: 0630
Type: SC 13D/A

Mailing Address BAARERSTRASSE 14 ZUG V8 CH-6300
Business Address BAARERSTRASSE 14 ZUG V8 CH-6300 6173154600
CRISPR Therapeutics AG (Subject) CIK: 0001674416 (see all company filings)

EIN.: 473173478 | State of Incorp.: V8 | Fiscal Year End: 1231
Type: SC 13D/A | Act: 34 | File No.: 005-89674 | Film No.: 171031684
SIC: 2836 Biological Products, (No Diagnostic Substances)